- Home
- SLNH vs LPCN Comparison
SLNH vs LPCN Comparison
Compare SLNH & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLNH
- LPCN
- Stock Information
- Founded
- SLNH 1961
- LPCN 1997
- Country
- SLNH United States
- LPCN United States
- Employees
- SLNH N/A
- LPCN N/A
- Industry
- SLNH EDP Services
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- SLNH Technology
- LPCN Health Care
- Exchange
- SLNH Nasdaq
- LPCN Nasdaq
- Market Cap
- SLNH 15.5M
- LPCN 16.1M
- IPO Year
- SLNH N/A
- LPCN N/A
- Fundamental
- Price
- SLNH $0.52
- LPCN $3.03
- Analyst Decision
- SLNH Hold
- LPCN Strong Buy
- Analyst Count
- SLNH 1
- LPCN 2
- Target Price
- SLNH N/A
- LPCN $9.00
- AVG Volume (30 Days)
- SLNH 1.5M
- LPCN 30.2K
- Earning Date
- SLNH 08-14-2025
- LPCN 08-05-2025
- Dividend Yield
- SLNH N/A
- LPCN N/A
- EPS Growth
- SLNH N/A
- LPCN N/A
- EPS
- SLNH N/A
- LPCN N/A
- Revenue
- SLNH $27,891,000.00
- LPCN $4,208,119.00
- Revenue This Year
- SLNH N/A
- LPCN N/A
- Revenue Next Year
- SLNH N/A
- LPCN N/A
- P/E Ratio
- SLNH N/A
- LPCN N/A
- Revenue Growth
- SLNH N/A
- LPCN N/A
- 52 Week Low
- SLNH $0.36
- LPCN $2.68
- 52 Week High
- SLNH $5.31
- LPCN $6.17
- Technical
- Relative Strength Index (RSI)
- SLNH 46.68
- LPCN 43.36
- Support Level
- SLNH $0.43
- LPCN $2.86
- Resistance Level
- SLNH $0.52
- LPCN $3.06
- Average True Range (ATR)
- SLNH 0.06
- LPCN 0.14
- MACD
- SLNH 0.01
- LPCN -0.01
- Stochastic Oscillator
- SLNH 66.67
- LPCN 28.45
About SLNH Soluna Holdings Inc.
Soluna Holdings Inc is a U.S.-based company that conducts operations through its subsidiary. The group is engaged in the mining of cryptocurrency through data centers that can be powered by renewable energy sources. The data centers buy every excess megawatt to use for batch-oriented, computing-intensive processes such as cryptocurrency mining or machine learning which is a low-risk and low-friction solution to use as a smartphone.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.